Sign in
Taking people in South KoreaNo phase

Virus-fighting T cells for children with viral infections after a stem cell transplant

Tests LB-DTK-MV T cells in young people with CMV, EBV or BKV infection after transplant.

Key facts

Who runs it
LucasBio
Where
Seoul, South KoreaSee the site
Trial code
Registry title
Evaluation of Safety and Efficacy of Virus Specific T-Cell Administration in Pediatric Patients With Systemic Viral Infection Following Allogeneic Hematopoietic Stem Cell Transplantation.
Status
Recruiting
People taking part
6 people, planned
Started
10 Feb 2026
Expected to end
20 May 2027
Type of study
Interventional
Treatments tested
  • LB-DTK-MV
Record updated
6 July 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for children and young people aged 1-25 years who had a donor stem-cell transplant and now have a CMV, EBV and/or BKV virus infection that did not respond to standard treatment.

Age
1 to 25 years
Sex
All sexes can join.
Disease stage
CMV, EBV and/or BKV infection that is resistant or refractory to standard treatment and linked to severe complications after a donor (allogeneic) stem-cell transplant. Neutrophil engraftment is shown (ANC 0.5x10^3/μL or higher for 3 days in a row). Complete donor chimerism (PCR-short tandem repeats ≥ 95%) at the first dose.
Earlier treatment
Must have had a donor stem-cell transplant at least 21 days before screening. Steroid dose must be reducible to 0.5mg/kg/day of Prednisolone (or equivalent) or less. Cannot have had ATG, Campath (Alemtuzumab) or other T-cell immunosuppressive antibodies in the 28 days before the first dose.
Biomarker or test result
Complete donor chimerism (PCR-short tandem repeats ≥ 95%) at the time of the first dose. Women who can become pregnant need a negative blood pregnancy test at screening.

Main reasons for not taking part

  • ATG, Campath (Alemtuzumab) or other T-cell immunosuppressive antibodies within 28 days before the first dose
  • Organ failure, uncontrolled bacterial or fungal infection, AST or ALT more than 5 times the upper limit of normal, or eGFR below 30mL/min/1.73m^2
  • Stem-cell transplant or donor lymphocyte infusion (DLI) within 28 days before the first dose
  • Active graft-versus-host disease (GvHD) of grade 2 or higher
  • Active malignant tumor or uncontrolled recurrence

The registry criteria, word for word

Show all 14 criteriaShow less

Who can take part

  • Patients with CMV, EBV, and/or BKV infection that is resistant or refractory to standard-of-care treatment and associated with severe complications following allogeneic hematopoietic stem cell transplantation at the ages of 1-25 years
  • Patients with evidence of neutrophil engraftment, defined as an absolute neutrophil count (ANC) maintained at 0.5x10\^3/μL or higher for 3 consecutive days following allogeneic hematopoietic stem cell transplantation
  • Patients who have undergone allogeneic hematopoietic stem cell transplantation at least 21 days prior to the screening visit
  • Patients who show complete donor chimerism (PCR-short tandem repeats ≥ 95%) at the time of first dose administration
  • Patients who are able to reduce their steroid dosage to 0.5mg/kg/day of Prednisolone (or an equivalent dose) or less
  • Individuals who have voluntarily decided to participate in this clinical study and have provided written consent to comply with the restrictions
  • For women of childbearing potential, those who tested negative on a pregnancy test (blood test) performed on the screening visit
  • Individuals deemed suitable as study subjects through screening tests (vital signs, physical examination, medical and surgical history, electrocardiogram, laboratory tests, etc.)

Who cannot take part

  • Individuals who have received treatment with ATG (Antithymocyte Globulin), Campath (Alemtuzumab), or other T-cell immunosuppressive monoclonal antibodies within 28 days prior to the first dose
  • Patients with active graft-versus-host disease (GvHD) of grade 2 or higher
  • Patients with active malignant tumor or uncontrolled recurrence
  • Patients with organ failures and/or uncontrolled bacterial or fungal infections; Moderate or severe liver damage [Aspartate aminotransferase (AST) or Alanine aminotransferase (ALT) > 5 times the upper limit of normal (ULN)]; Chronic kidney disease [eGFR < 30mL/min/1.73m\^2]
  • Patients who have undergone allogeneic hematopoietic stem cell transplantation or received donor lymphocyte infusion (DLI) within 28 days prior to the scheduled first dose
  • Patients deemed ineligible for participation in this clinical study by the investigator

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 1 and 25 years old?

Where in South Korea

  • The Catholic University of Korea, Seoul ST. Mary's HospitalSeoul, South KoreaContact: Jae-won Yoo, MD-PhD (principal investigator)Taking people

About the trial

What the trial wants to find out

The goal of this prospective clinical study is to evaluate the safety and efficacy of Multi-Virus Specific T cells (LB-DTK-MV) in pediatric patients with systemic viral infection, including CMV, EBV, and BKV, after allogeneic hematopoietic stem cell transplantation (allo-HSCT). The main questions it aims to answer are:

Read full original descriptionShow less

* What is the maximum tolerated dose of LB-DTK-MV based on dose-limiting toxicity? * What treatment emergent adverse events occur within 14 days after the second infusion? * Is there a clinically significant reduction in CMV, EBV, and BKV viral loads within 14 days following the second infusion? * Is there a clinically significant improvement in clinical symptoms within 14 days following the second infusion?

Participants will:

* Receive a single intravenous infusion of LB-DTK-MV during the baseline visit (low dose: 1x10\^7/m\^2; high dose: 2x10\^7/m\^2). * Receive the second infusion of LB-DTK-MV intravenously at the same dose 14 days after the first infusion. * Attend weekly follow-up visits at the clinic for 6 months after the first infusion.

The group in the trial

  • Experimental Group (All, ped)Treatment being tested

    Treatment: LB-DTK-MV

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Prospective Clinical Study to Evaluate the Safety and Efficacy of Virus Specific T-Cell Administration in Pediatric Patients With Systemic Viral Infection Following Allogeneic Hematopoietic Stem Cell Transplantation.
Plain-language title
Virus-fighting T cells for children with viral infections after a stem cell transplantGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Fit questions
Built from NCT07685457, who can take part
Record updated
6 July 2026